STOCK TITAN

Gain Therapeutics Inc - GANX STOCK NEWS

Welcome to our dedicated news page for Gain Therapeutics (Ticker: GANX), a resource for investors and traders seeking the latest updates and insights on Gain Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Gain Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Gain Therapeutics's position in the market.

Rhea-AI Summary
Gain Therapeutics, Inc. (GANX) announces submission of HREC application for Phase 1 clinical study of GT-02287. Positive preclinical results and upcoming milestones highlighted.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.33%
Tags
earnings
-
-
Rhea-AI Summary
Gain Therapeutics to participate in fireside chat at 2023 BTIG Virtual Biotechnology Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.06%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.34%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.39%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.43%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.47%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.99%
Tags
conferences clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.24%
Tags
earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.84%
Tags
conferences
Gain Therapeutics Inc

Nasdaq:GANX

GANX Rankings

GANX Stock Data

60.42M
14.31M
16.2%
10.35%
0.83%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Bethesda

About GANX

gain therapeutics is a preclinical stage biotech company specializing in the discovery of new drugs for orphan diseases. the company targets inborn errors of metabolism; a group of rare diseases of genetic origin with a high unmet medical need. gain therapeutics is also working on a new class of compounds: non-competitive pharmacological chaperones, identified through its innovative proprietary platform – see-tx. the gain therapeutics team is made up of a group of drug discovery and development experts with several decades of experience in biotech and pharma.